The International Journal of Biological Markers · 2017 · 12 citations · 23 references
MedicineOncologyPathologyMetastasisMolecular OncologyNeoplasiaBone MetastasisMalignant NeoplasmsMetastatic Bone DiseaseMolecular Tumor ProfilingProstate CancerTumor MarkersCancer Metastasis BiomarkersCastration-resistant Prostate Cancer TherapyCathepsin ActivityGleason ScoringMetastasis Of Prostate CancerMetastatic Castration-resistant Prostate CancerNeoplastic DiseaseTissue Microarrays
BACKGROUND: The lysosomal cysteine protease cathepsin K is involved in bone remodeling and is also expressed in the peritumoral stroma of carcinomas arising from different organs. A new generation of cathepsin K inhibitors blocking the RANKL/RANK pathway are being developed. We sought to investigate cathepsin K expression in a cohort of castration-resistant prostate carcinomas. METHODS: Sixteen cases of castration-resistant disease with at least 5 years of follow-up were selected from a cohort of 280 patients who underwent surgery. Cathepsin K was evaluated on formalin-fixed and paraffin-embedded tissue microarrays with 5 tissue spots per case. These were scored as high 2+ (≥30% of cells), low 1+ (<30% of cells) or zero (absence), distinguishing tumor cells and peritumoral stroma cells. Low (1+) and absence (0) of scoring were interpreted as negative, and high (2+) as positive. RESULTS: The castration-resistant group was composed of 15 acinar adenocarcinomas and 1 neuroendocrine carcinoma, and all showed at least Gleason score 8 at prostatectomy. Two out of 16 cases (12%) scored positive for cathepsin K in tumor cells; and 5 of 16 cases (31%) scored positive in peritumoral stroma cells. The neuroendocrine and acinar subtypes of carcinoma with positive immunoexpression in neoplastic cells developed bone metastases after 4 and 5 years, respectively, and subsequently died. CONCLUSIONS: Patients affected by castration-resistant prostate carcinoma may be tested for cathepsin K, and a positive strong expression (2+) could be a useful predictive biomarker of response to targeted agents, aiding in the selection of patients eligible for these treatments.
23
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency
Bruce D. Gelb, Guo‐Ping Shi, Harold A. Chapman et al. · Science · 1996 · 1K citations